MedTrace Logo

Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN

NCT03880396 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2022-07-26

No results posted yet for this study

Summary

The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

RADIATION

hypofractionated Rth with platinol

hypofractionated Rth with weekly cisplatin 40mg/m2

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Doaa G Abdelnaser Fathy Mahmoud, Doctor · Assiut University

  • Hoda H Essa, Doctor · Assiut University

  • Aiat M Mohammed, Doctor · Assiut University

  • Mohamed O Gad, Doctor · Assiut University

  • Nora Essam · South Egypt Cancer Institute

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-10
Primary Completion
2020-12-26
Completion
2020-12-26

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03880396 on ClinicalTrials.gov